ライフサイエンスコーパス: LEMS

1 LEMS analyses of single analytes as a function of concen

2 LEMS analysis of the powders revealed several new mass s

3 LEMS antibodies inhibit Ca2+ currents in excitable cells

4 LEMS antibody treatment increased the percentage of trai

5 LEMS imaging of the spatial distribution of an oxycodone

6 Lung cancer was detected in 44/87 (51%) LEMS patients.

7 cit in neurotransmitter release magnitude at LEMS model NMJs.

8 tive increase in neurotransmitter release at LEMS model NMJs.

9 Weight loss >= 5%, tobacco use at LEMS onset and age at onset >= 50 years were independent

10 tive cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a r

11 symptoms and signs cannot be used to exclude LEMS from the differential diagnosis.

12 There is no cure for LEMS, and the current most commonly used symptomatic tre

13 represents a promising treatment option for LEMS and potentially for other disorders of the NMJ.

14 possible alternative treatment strategy for LEMS.

15 -type channels was abolished by four of four LEMS IgG preparations, that subserved by Q-type channels

16 vas deferens of mice injected with IgG from LEMS patients or from controls.

17 ce by repeated administration of plasma from LEMS patients reduces the amplitude of the perineurial P

18 The pathogenic role of anti-VGCC antibody in LEMS is well established.

19 ponse of the ACh release apparatus occurs in LEMS.

20 elopment of small-cell lung cancer (SCLC) in LEMS patients in multivariable analysis.

21 Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity des

22 CD19 CAR T cells for treating concomitant MG/LEMS.

23 elp distinguish between tumour and nontumour LEMS.

24 dissuade some colleagues from a diagnosis of LEMS.

25 The effect of LEMS antibodies on Ca2+ currents and exocytosis was stud

26 The hallmark of LEMS is a large potentiation of neuromuscular transmissi

27 esis using a mouse passive transfer model of LEMS.

28 characteristic electrophysiological signs of LEMS: reduced quantal content and facilitation of EPP am

29 prediction score, calculated at the time of LEMS diagnosis, is an effective tool for cancer screenin

30 on to ACh release during passive transfer of LEMS appears to occur only after quantal release is sign

31 Passive transfer of LEMS to mice by repeated administration of plasma from L

32 treated for 2 or 24 h with either control or LEMS plasma, or following chronic treatment with control

33 in 8 patients, also were observed among our LEMS population.

34 al oculobulbar feature occurred in 13 of our LEMS patients.

35 Purified LEMS IgGs from five patients inhibited N- and P/Q-type C

36 A-P scores were significantly higher in SCLC-LEMS patients (3.5, 95% CI 3 to 4) compared to non-tumou

37 ion of the laser electrospray mass spectral (LEMS) measurements resulted in perfect classification of

38 ed for laser electrospray mass spectrometry (LEMS) and electrospray ionization-mass spectrometry (ESI

39 Laser electrospray mass spectrometry (LEMS) coupled with offline multivariate statistical anal

40 second laser electrospray mass spectrometry (LEMS) experiments, suggesting that the fiber-based femto

41 Laser electrospray mass spectrometry (LEMS) is demonstrated for pharmaceutical samples at atmo

42 using laser electrospray mass spectrometry (LEMS) reveal monotonic signal response as a function of

43 using laser electrospray mass spectrometry (LEMS).

44 including Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar ataxia (PCA).

45 (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are autoimmune disorders affecting neuromuscular t

46 Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder in which autoantibodi

47 Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease that affects neurotransmi

48 Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder in which a significant f

49 (78%) of Lambert-Eaton myasthenic syndrome (LEMS) patients evaluated at the Lahey Clinic (Table).

50 h-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumour Association Prediction (DELTA-P) score in a

51 In Lambert-Eaton myasthenic syndrome (LEMS), SOX antibodies help distinguish between tumour an

52 utoimmune Lambert-Eaton myasthenic syndrome (LEMS).

53 utoimmune Lambert-Eaton myasthenic syndrome (LEMS).

54 ificant charge reduction was observed in the LEMS experiment while the ESI measurement revealed charg

55 component analysis and discrimination of the LEMS mass spectral measurements resulted in perfect clas

56 In contrast to the LEMS experiments, the intensity ratios from control expe

57 Thus, LEMS IgG impairs transmitter release from parasympatheti

58 even after very short periods of exposure to LEMS plasma.

59 (3.5, 95% CI 3 to 4) compared to non-tumour-LEMS (2, 95% CI 1 to 2) (P < 0.0001).

60 ers and fillers in intact formulations using LEMS.

61 so reduced in muscles incubated acutely with LEMS plasma.

62 Incubation for 18 h with LEMS IgG (2 mg/ml) caused a significant dose-dependent r

63 aphragms from naive mice were incubated with LEMS or control human plasma for 2 or 24 h.

64 Treatment of mice with LEMS plasma evoked the characteristic electrophysiologic

65 ubated cultured rat cerebellar neurones with LEMS IgG and observed a reduction in P-type current in P

66 Clinical features from 87 patients with LEMS, occurring within three months from disease onset,

67 from healthy human controls or patients with LEMS.

68 However, following 30 days treatment with LEMS plasma, nimodipine significantly reduced the remain

69 after chronic, but not acute treatment with LEMS plasma.